Overview

Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19)

Status:
Active, not recruiting

Trial end date:
2021-08-28

Target enrollment:

Participant gender:

Summary

In December 2019, a group of patients with pneumonia of unknown cause was identified in Wuhan, in the Hubei province, China. Despite the need of target specific therapeutic options for COVID-19, until now there is no proof of effectiveness of any specific intervention. Some limited observational trials and also evidence from randomized trials have shown no benefit of hydroxychloroquine in inpatient context. Thus, studies evaluating interventions in an outpatient setting in non-severe patients can provide important information related to prognosis and safety. In this way, the present study will evaluate the effectiveness and safety of the use of hydroxychloroquine in COVID-19 outpatients by means of a Randomized, double-blind, placebo-controlled trial

Phase:

Phase 4

Details

Lead Sponsor:

Hospital Alemão Oswaldo Cruz

Collaborators:

Brazilian Research In Intensive Care Network
EMS S/A
Hospital do Coracao
Hospital Israelita Albert Einstein
Hospital Moinhos de Vento
Hospital Sirio-Libanes

Treatments:

Hydroxychloroquine